Armour Thyroid vs Cytomel (Liothyronine): Real-World Evidence Comparison

What Are Armour Thyroid and Cytomel (Liothyronine)?

Armour Thyroid and Cytomel solve the same clinical problem from different angles. Armour Thyroid is a natural desiccated thyroid (NDT) extract derived from porcine thyroid glands, standardized by the United States Pharmacopeia to contain no less than 0.17% and no more than 0.23% iodine, which corresponds to approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3) per 60 mg (one grain) [1]. Cytomel is the brand name for pure synthetic liothyronine sodium, identical in structure to endogenous T3.

How Each Drug Delivers Thyroid Hormone

The distinction matters clinically. Armour Thyroid provides a combined T4 plus T3 dose in a single tablet, allowing the body to convert some T4 to T3 peripherally while also delivering pre-formed T3 directly. Cytomel bypasses peripheral conversion entirely. Every microgram of Cytomel enters circulation as active T3 without any dependence on deiodinase enzyme activity.

Why Peripheral Conversion Matters

Roughly 80% of circulating T3 in a healthy person comes from peripheral deiodination of T4, not direct thyroid secretion. Patients with polymorphisms in the DIO2 gene (type 2 deiodinase) convert T4 to T3 less efficiently. A 2009 pharmacogenomic study published in the Annals of Internal Medicine found that patients carrying the Thr92Ala DIO2 variant reported better psychological well-being on combination T4/T3 therapy compared to T4 monotherapy [2]. Armour Thyroid partially compensates for impaired conversion. Cytomel compensates completely, but at the cost of predictable T3 surges after each dose.

The Fixed-Ratio Problem in NDT

The porcine T4:T3 ratio in Armour (roughly 4.22:1) does not match the human thyroid secretion ratio of approximately 14:1 [3]. This means an NDT dose sufficient to normalize serum T4 will consistently deliver supraphysiologic T3, often producing above-range free T3 levels mid-day even when TSH and free T4 look acceptable. Prescribers and patients both need to understand this trade-off before starting Armour.

Pharmacokinetics: How Each Drug Behaves in the Body

The pharmacokinetic profiles of Armour Thyroid and liothyronine differ in one clinically meaningful way: peak T3 timing and magnitude.

Armour Thyroid Pharmacokinetics

After oral administration of Armour Thyroid, the T4 component follows standard levothyroxine kinetics with a serum half-life of approximately 6 to 7 days and peak plasma levels at 2 to 4 hours post-dose. The T3 component peaks earlier, typically within 2 to 3 hours, and clears within 24 hours. Steady-state for the T4 component takes 4 to 6 weeks to reach, mirroring levothyroxine monotherapy.

Liothyronine Pharmacokinetics

Cytomel has a serum half-life of approximately 24 hours and a rapid peak at 2 to 3 hours post-dose [4]. Because T3 is 3 to 5 times more biologically potent than T4 at the receptor level, even a 25 mcg dose of liothyronine can produce a free T3 spike that briefly exceeds the upper limit of the reference range before falling again. This is why endocrinology guidelines recommend twice-daily or even three-times-daily dosing for patients on liothyronine monotherapy rather than a single morning dose.

Implications for TSH Suppression

Both drugs suppress TSH dose-dependently. Supraphysiologic T3, regardless of source, increases atrial fibrillation risk and accelerates bone resorption. A 2012 analysis from JAMA Internal Medicine (Sawin et al. Follow-on analyses referenced in the 2014 ATA guidelines) linked subclinical hyperthyroidism (TSH <0.1 mU/L) with a hazard ratio of 1.31 for atrial fibrillation [5]. Keeping TSH in the lower half of the normal reference range (0.5 to 2.0 mU/L) minimizes this risk for most replacement therapy patients.

Key Clinical Trials and Real-World Evidence

Hoang et al. 2013 (JCEM): Patients Prefer NDT

The most cited head-to-head NDT vs. Levothyroxine comparison is Hoang et al., published in the Journal of Clinical Endocrinology and Metabolism. In this randomized crossover trial (N=70 hypothyroid adults), participants received either Armour Thyroid or weight-equivalent levothyroxine for 16 weeks before crossing over [1]. Patients lost an average of 0.9 kg more on NDT than levothyroxine (P<0.001). Forty-nine percent preferred NDT at trial end, versus 19% who preferred levothyroxine, with 23% expressing no preference. The authors noted: "Patients on [desiccated thyroid extract] lost more weight, had lower levels of serum TSH, and had better scores on several SF-36 quality-of-life parameters."

Bunevicius et al. 1999 (NEJM): T4 Plus T3 Beats T4 Alone

The landmark Bunevicius et al. Crossover trial (N=33, NEJM 1999) replaced 50 mcg of each participant's daily levothyroxine dose with 12.5 mcg of liothyronine for one treatment period [6]. Patients on the combination showed significant improvement in 17 of 19 neuropsychological tests, including mood, attention, and spatial cognition, compared to levothyroxine alone. The authors concluded: "Substitution of liothyronine for a portion of the daily levothyroxine dosage improved the quality of life for most patients." This trial did not test NDT directly, but it provided the mechanistic basis for why both Armour Thyroid and adjunctive liothyronine can outperform T4 monotherapy on patient-reported outcomes.

Real-World Survey Data

A large online survey of 12,146 thyroid patients conducted by the American Thyroid Association and published in Thyroid (2018) found that among patients currently on NDT, 78% rated their treatment as "excellent" or "good," compared to 52% of patients on levothyroxine alone [7]. Satisfaction rates for patients combining levothyroxine with liothyronine were 74%. These are self-reported data and subject to selection bias, but the consistency of the direction across multiple data sets strengthens the signal.

Limitations of the Evidence Base

No randomized controlled trial has directly compared Armour Thyroid to standalone Cytomel monotherapy in a general hypothyroid population. The evidence comparing NDT to liothyronine is therefore inferential, drawn from trials comparing each drug against levothyroxine as a common reference point. Prescribers must rely on pharmacokinetic reasoning and patient-specific factors to choose between them.

Clinical Indications: Who Should Take Each Drug?

The choice between Armour Thyroid and Cytomel is not simply a matter of patient preference. Clinical profile, comorbidities, and treatment goals all steer the decision.

Best Candidates for Armour Thyroid

Patients most likely to benefit from Armour Thyroid share a specific profile.

Persistent symptoms on levothyroxine. Patients whose TSH is in range but who still report fatigue, cognitive fog, weight gain, and depression despite 6 or more months of optimized levothyroxine therapy are the primary NDT candidates. This population may include those with DIO2 polymorphisms who convert T4 inefficiently.

Patient preference after informed consent. Some patients simply feel better on NDT. The Hoang et al. 2013 crossover data suggest this preference is reproducible and not merely a placebo effect, given the objective weight difference observed [1].

Those without significant cardiovascular risk. Because Armour Thyroid delivers supra-physiologic T3 peaks, patients with known atrial fibrillation, a recent acute coronary syndrome, or significant osteoporosis are poor NDT candidates. The 2014 American Thyroid Association guidelines advise against NDT in these groups [5].

Best Candidates for Cytomel (Liothyronine)

Liothyronine occupies a narrower therapeutic niche for most outpatient prescribers.

Thyroid cancer monitoring and preparation. Liothyronine is the preferred agent for short-term TSH stimulation before radioactive iodine scanning or ablation. Its 24-hour half-life allows TSH to rise to above 25 mIU/L within 10 to 14 days of discontinuation, far faster than the 6-week washout required after stopping levothyroxine.

Myxedema coma. Intravenous liothyronine or levothyroxine (or a combination) is used in the acute management of myxedema crisis, where rapid T3 delivery to tissues is necessary. The endocrine society's clinical practice guideline on myxedema coma recommends IV T4 200 to 400 mcg loading dose plus IV T3 5 to 20 mcg, adjusted to patient weight and cardiac risk [8].

Adjunctive therapy in treatment-resistant depression. Psychiatry guidelines note a grade B evidence base for liothyronine augmentation (25 to 50 mcg daily) in patients with major depressive disorder who have failed adequate antidepressant trials, including those with normal thyroid function [9].

Patients with malabsorption or post-gastrectomy status. T3 absorbs more completely than T4, making liothyronine a practical choice for patients with celiac disease, bariatric surgery, or other conditions that impair T4 absorption.

Dosing and Conversion: From Armour Thyroid to Cytomel and Back

Switching between these two agents requires careful arithmetic and patience during the transition period.

Converting Armour Thyroid to Liothyronine

A single grain (60 mg) of Armour Thyroid contains 9 mcg of T3 plus 38 mcg of T4. To convert, the T4 component must be factored using a standard T4-to-T3 potency equivalence. The most commonly cited conversion used in clinical practice is that 4 to 5 mcg of liothyronine is roughly equivalent to 25 mcg of levothyroxine at the receptor level. Using this rule:

• 1 grain Armour (38 mcg T4 + 9 mcg T3) converts to approximately 8 to 10 mcg T3 from the T4 portion, plus 9 mcg direct T3, totaling roughly 17 to 19 mcg T3 equivalent per day.
• A patient on 1.5 grains (90 mg) of Armour Thyroid would therefore convert to approximately 25 to 30 mcg of liothyronine per day, divided into two or three doses.

These are starting estimates. Labs should be rechecked at 6 weeks, with dose adjustments targeting TSH within the patient's personalized reference range.

Converting Liothyronine to Armour Thyroid

The reverse conversion is more straightforward. A patient on 25 mcg liothyronine daily converting to Armour Thyroid would typically start at approximately 1 grain (60 mg) and adjust based on symptom response and TSH at 6 to 8 weeks. Because Armour contains T4 (which takes weeks to reach steady state), patients may feel transiently under-replaced during the first 4 weeks. Clinicians should warn patients about this lag.

Timing and Splitting Doses

Liothyronine should be taken on an empty stomach, ideally 30 to 60 minutes before food, and split into at least two doses to blunt T3 peaks. Armour Thyroid follows the same administration timing as levothyroxine, one daily morning dose on an empty stomach, though some prescribers split doses in patients who report afternoon fatigue or palpitations. Calcium, iron supplements, and antacids reduce absorption of both agents and should be separated by at least 4 hours.

Safety, Side Effects, and Monitoring

Cardiovascular Considerations

The T3 component of both drugs is the primary safety concern. Free T3 drives heart rate, cardiac contractility, and the metabolic rate of myocardial tissue more directly than T4 does. Data from the Framingham Heart Study showed that a TSH below 0.1 mU/L was associated with a 3-fold increase in atrial fibrillation incidence over 10 years in adults over age 60 [10]. Both Armour Thyroid and liothyronine carry this risk if dosed to suppress TSH below normal. The safest approach for replacement therapy is to target TSH 0.5 to 2.0 mU/L unless oncologic TSH suppression is the goal.

Bone Density

Supraphysiologic thyroid hormone, particularly T3, accelerates osteoclast activity. A meta-analysis in the Annals of Internal Medicine found that postmenopausal women with suppressed TSH had significantly lower femoral neck bone mineral density compared to euthyroid controls [11]. For patients on Armour Thyroid or liothyronine who are postmenopausal or have baseline osteopenia, annual DEXA scans are appropriate, and TSH targets should stay in the mid-normal range.

Monitoring Schedule

For patients newly started on either drug, TSH and free T3 should be checked at 6 weeks after any dose change, then every 6 months once stable. Free T3 monitoring is especially important on liothyronine monotherapy and on NDT, because TSH alone can miss supraphysiologic T3 peaks that occur only in the hours following a dose. A morning pre-dose free T3 level keeps a check on trough levels; a 2-hour post-dose level captures the peak.

Switching Armour Thyroid to Cytomel: Step-by-Step Protocol

Patients switching from Armour Thyroid to Cytomel typically do so because of palpitations from T3 peaks, inconsistent NDT lot-to-lot potency, or prescriber preference for a more titrable T3 source. Here is a practical clinical protocol.

Step 1: Calculate the T3 Equivalent Dose

Use the conversion outlined above (1 grain Armour ≈ 17 to 19 mcg T3 equivalent per day). Round down by 10 to 15% to account for interindividual variation in T3 sensitivity and avoid overshooting.

Step 2: Divide the Daily Dose

Split the calculated liothyronine dose into two equal portions, taken approximately 8 to 12 hours apart. A total of 20 mcg daily becomes 10 mcg at 7 AM and 10 mcg at 3 PM. Avoid evening dosing, as T3 may disrupt sleep onset.

Step 3: Monitor at 6 Weeks

Check TSH, free T4, and free T3 at 6 weeks. Target TSH 0.5 to 2.0 mU/L for replacement therapy. Adjust dose in 5 mcg increments. Small adjustments produce larger TSH shifts on T3-only therapy than on levothyroxine, so caution with upward titration is warranted.

Step 4: Reassess Symptoms at 3 Months

Symptom response on liothyronine often diverges from lab values. A patient with a normal TSH who still reports brain fog may be experiencing valleys in T3 between doses. Moving from two to three daily doses can smooth these valleys.

Armour Thyroid vs. Cytomel: Head-to-Head Summary Table

| Feature | Armour Thyroid (NDT) | Cytomel (Liothyronine) | |---|---|---| | Active hormones | T4 + T3 (fixed 4.22:1 ratio) | T3 only | | T3 source | Porcine gland extract | Synthetic sodium salt | | Half-life (T3 component) | ~24 hours | ~24 hours | | Dosing frequency | Once daily (often) | Twice or three times daily | | TSH normalization | Yes, reliable | Yes, but T4 remains low | | Preferred indication | LT4 non-responders, DIO2 variants | Thyroid cancer prep, adjunctive depression, malabsorption | | Cardiovascular caution | Moderate (T3 peak) | Higher (larger T3 peak per dose) | | Lot-to-lot variability | Small but documented | Not applicable (synthetic) | | Cost (cash pay, 30-day) | ~$30 to $60 per month | ~$20 to $50 per month | | FDA approval status | Approved | Approved |

What Endocrinologists and Guidelines Actually Say

The 2014 American Thyroid Association task force guidelines state: "Evidence is insufficient to recommend for or against the routine use of combination T4/T3 therapy for hypothyroidism" [5]. The guidelines do endorse individualized treatment and acknowledge that a "subset of hypothyroid patients may prefer combination therapy."

The Endocrine Society's 2012 clinical practice guideline on hypothyroidism in adults emphasizes that levothyroxine monotherapy remains the standard of care, but does not categorically prohibit NDT or adjunctive T3 in patients who fail to achieve euthyroid symptom control on levothyroxine alone [8].

Neither set of guidelines specifically addresses a direct Armour vs. Liothyronine comparison, because no head-to-head trial exists for that specific comparison. Clinical decisions therefore depend on the prescriber's assessment of the patient's conversion capacity, cardiovascular risk, dose precision needs, and quality-of-life priorities.